Study of the lipid-lowering action of choloxin and Nilevar in patients with chronic renal failure
- 1 December 1974
- journal article
- clinical trial
- Published by Oxford University Press (OUP)
- Vol. 50 (590), 737-740
- https://doi.org/10.1136/pgmj.50.590.737
Abstract
Summary: Lowering of lipids in patients with chronic renal failure is advantageous but cannot be done by calorie restriction. In a controlled study the anabolic steroid norethandrolone (Nilevar) was found to lower triglycerides by 50%, while D-thyroxine (Choloxin) lowered the cholesterol by 25%. Both drugs increased the activity of lipoprotein lipase in spite of uraemic inhibition. Norethandrolone also reduced basal serum insulin levels. Norethandrolone seems appropriate for underweight patients and D-thyroxine for overweight patients, but side effects are more frequent than in non-uraemic patients.Keywords
This publication has 29 references indexed in Scilit:
- TRIGLYCERIDE METABOLISM IN THYROID DISEASEThe Lancet, 1973
- Increase of Post-Heparin Lipase Activity by Oxandrolone in Familial HyperchylomicronemiaScandinavian Journal of Clinical and Laboratory Investigation, 1973
- DIETARY MANAGEMENT IN RENAL FAILUREThe Lancet, 1972
- HYPERLIPOPROTEINEMIA IN PATIENTS WITH CHRONIC RENAL FAILUREActa Medica Scandinavica, 1972
- CHANGE OF LIPOPROTEIN PATTERN BY CLOFIBRATE IN HYPERGLYCERIDAEMIA AND MIXED HYPERLIPIDAEMIAActa Medica Scandinavica, 1972
- Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemiaMetabolism, 1971
- DEXTROTHYROXINE WITH PROPRANOLOL IN TREATMENT OF HYPERCHOLESTEROLqMIAThe Lancet, 1971
- Uremic lipemia. An unrecognized abnormality in triglyceride production and removalArchives of Internal Medicine, 1970
- ISCHIEMIC HEART-DISEASE AS A COMPLICATION OF NEPHROTIC SYNDROMEThe Lancet, 1969
- The colorimetric micro-determination of non-esterified fatty acids in plasmaClinica Chimica Acta; International Journal of Clinical Chemistry, 1964